RECOVERY Trial shows baricitinib reduces deaths in COVID-19 hospitalised patients, NIHR
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth.
The benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments which have previously been shown to reduce the risk of death in these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2022 Category: Consumer Health News Source Type: news
Continued Dexamethasone at Discharge Not Tied to Better COVID-19 Outcomes
WEDNESDAY, March 9, 2022 -- For individuals hospitalized with COVID-19, continuing treatment with dexamethasone at discharge is not associated with a reduction in 14-day all-cause readmission or mortality, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS
...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
COVID antiviral Molnupiravir to be tested in RECOVERY trial on hospitalised patients
The RECOVERY Trial was launched as an emergency response in March 2020 and has so far discovered three effective treatments for COVID-19 - the inexpensive steroid dexamethasone; the arthritis drug tocilizumab; and an artificial antibody treatment, now known as Ronapreve. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 24, 2022 Category: Pharmaceuticals Source Type: news
Dexamethasone Effective as an Analgesic Adjuvant in Total Knee Replacement Dexamethasone Effective as an Analgesic Adjuvant in Total Knee Replacement
Two doses of dexamethasone given in the perioperative period reduced morphine consumption during 48 hours after total knee arthroplasty in the randomized, placebo-controlled DEX-2-TKA trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 18, 2022 Category: Orthopaedics Tags: Anesthesiology News Source Type: news
Adding a SN Block to TKA When NSAIDs are Contraindicated Adding a SN Block to TKA When NSAIDs are Contraindicated
Might a low concentration of popliteal-sciatic nerve block and dexamethasone be an effective adjunct for early postoperative pain control in patients intolerant of NSAIDs?BMC Anesthesiology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 11, 2022 Category: Orthopaedics Tags: Anesthesiology Journal Article Source Type: news
HiDex 6 day (Dexamethasone Tablets USP, 1.5 mg) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2021 Category: Drugs & Pharmacology Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Time-Saving Combo for R/r Multiple Myeloma FDA Approves Time-Saving Combo for R/r Multiple Myeloma
The US Food and Drug Administration this week approved daratumumab + hyaluronidase-fihj and carfilzomib plus dexamethasone – a combination that features quickly administered subcutaneous daratumumab.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study
Cohort study (n=565) found 15% of mechanically ventilated patients with COVID-19 had proven or probable COVID-19-associated pulmonary aspergillosis (CAPA). Age>62yrs, treatment with dexamethasone and>14 days mechanical ventilation were associated with increased risk. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2021 Category: Consumer Health News Source Type: news
Scientists sharing Omicron data were heroic. Let ’s ensure they don’t regret it | Jeffrey Barrett
The teams in Africa who detected the new Covid genome moved quickly. Their actions should not result in economic loss•Coronavirus – latest updates•See all our coronavirus coverageOne of the positive experiences during two years of pandemic gloom has been the speed of scientific progress in understanding and treating Covid. Many effective vaccines were launched in less than a year and rapid large-scale trials found a cheap and effective drug, dexamethasone, thatsaved thousands of lives.The global scientific community has also carried out “genomic surveillance” – sequencing the genome of the virus to track how it...
Source: Guardian Unlimited Science - November 28, 2021 Category: Science Authors: Jeffrey Barrett Tags: Coronavirus Science Infectious diseases World news Africa Epidemics World Health Organization Society Travel Source Type: news
